Business Description
Mustang Bio Inc
NAICS : 325414
SIC : 2836
ISIN : US62818Q3020
Total Employee Number:
4Description
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.52 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 89.8 | |||||
3-Year EPS without NRI Growth Rate | 90.8 | |||||
3-Year FCF Growth Rate | 86.6 | |||||
3-Year Book Growth Rate | -82.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.07 | |||||
9-Day RSI | 41.22 | |||||
14-Day RSI | 44.3 | |||||
3-1 Month Momentum % | -1.37 | |||||
6-1 Month Momentum % | -31.51 | |||||
12-1 Month Momentum % | -69.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.12 | |||||
Quick Ratio | 2.12 | |||||
Cash Ratio | 2.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -232.8 | |||||
Shareholder Yield % | 4.67 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -39.58 | |||||
ROA % | -16.71 | |||||
ROIC % | -3186.02 | |||||
3-Year ROIIC % | -418.29 | |||||
ROC (Joel Greenblatt) % | -716.15 | |||||
ROCE % | -46.05 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.59 | |||||
Price-to-Tangible-Book | 0.59 | |||||
EV-to-EBIT | 3.78 | |||||
EV-to-EBITDA | 3.78 | |||||
EV-to-Forward-Revenue | 194.79 | |||||
EV-to-FCF | 2.51 | |||||
| Price-to-Net-Current-Asset-Value | 0.59 | |||||
| Price-to-Net-Cash | 0.61 | |||||
Earnings Yield (Greenblatt) % | 26.46 | |||||
FCF Yield % | -97.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mustang Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.47 | ||
| Beta | 2.4721 | ||
| 3-Year Sharpe Ratio | -1.05 | ||
| 3-Year Sortino Ratio | -1.44 | ||
| Volatility % | 77.36 | ||
| 14-Day RSI | 44.3 | ||
| 14-Day ATR ($) | 0.061022 | ||
| 20-Day SMA ($) | 0.70056 | ||
| 12-1 Month Momentum % | -69.43 | ||
| 52-Week Range ($) | 0.5306 - 2.6 | ||
| Shares Outstanding (Mil) | 7.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mustang Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mustang Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-22 09:00 | In 162 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 24 days | ||
| First quarter earnings results for 2026 | 2026-05-05 | 0.75 (-1.05%) | ||
| Annual report for 2025 | 2026-03-19 | 0.86 (-1.42%) | ||
| General meeting for 2025 | 2025-12-22 09:00 | 1.09 (+1.87%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 1.26 (-4.55%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 1.52 (+3.40%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 1.12 (-0.88%) | ||
| Annual report for 2024 | 2025-03-28 | 1.42 (+2.16%) |
Show
Entries
Mustang Bio Inc Frequently Asked Questions
What is Mustang Bio Inc(MBIO)'s stock price today?
The current price of MBIO is $0.68. The 52 week high of MBIO is $2.60 and 52 week low is $0.53.
When is next earnings date of Mustang Bio Inc(MBIO)?
The next earnings date of Mustang Bio Inc(MBIO) is 2026-08-07 Est..
Does Mustang Bio Inc(MBIO) pay dividends? If so, how much?
Mustang Bio Inc(MBIO) does not pay dividend.
Guru Commentaries on NAS:MBIO
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Waitr Holdings, Mustang Bio, Party City Holdco, General Electric, or Delta Air Lines? | 2020-08-17 |
Articles on Mustang Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers